The prevalence of MetS in cohort BE, and in particular the relationship between the extent of BE and the change in leptin, insulin and other pro inflammatory markers in plasma, indicates that changes in the mucosa of patients with BE can be continuous and affected by metabolic changes in antacids and cytokines (32). This evidence concerns the gene INS and metabolic syndrome.